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ABSTRACT
We have investigated the effects of iodine (I) intake on urinary I
excretion in preterm (PT) babies up to 2 months after birth and its
effect on serum T4, free T4 (FT4), T3, TSH, and thyroglobulin (Tg)
levels compared to those in term (T) newborns.
Very premature and very sick infants were in negative I balance
for the first weeks after birth. Later, these same infants, as well as
the other PT and T newborns, were in positive balance; 75–80% of the
ingested I was not accounted for in the urine. The urinary I levels of
PT and T neonates cannot be equated to their I intakes.
T4, FT4, and T3 levels in PT and T neonates increased with post-
menstrual age, whereas Tg decreased and TSH did not change. Serum
FT4, T3, Tg, and TSH levels in PT neonates were affected negatively,
independently from age, by a low I intake. PT birth also affected T4,
FT4, and Tg negatively, independently from I intake and postmen-
strual age, for at least 6–8 weeks after birth.
Care should be taken to avoid I deficiency in PT neonates. However,
even when I intake is adequate, PT newborns are hypothyroxinemic
compared to T babies during an important period of brain develop-
ment. This suggests the possible convenience of interventions that
might mimic the intrauterine hormone environment and accelerate
maturation. (J Clin Endocrinol Metab 82: 1704–1712, 1997)
DURING THE first half of gestation, thyroid hormoneavailable to the fetus is predominantly of maternal
origin (1). Once fetal thyroid secretion starts, fetal supplies
are of mixed fetal and maternal origin. Although fetal thy-
roidal secretion is believed to constitute an increasing pro-
portion of the hormone available to the developing fetus,
maternal transfer of T4 may still contribute significantly to
fetal needs (20–50% of normal values) up until term (2),
mitigating the consequences of an inadequate fetal thyroid
function (3). Although the capacity to synthesize thyroglob-
ulin (Tg), to concentrate iodine (I), and to synthesize T4 and
T3 may start earlier, secretion of iodinated hormones by the
fetal thyroidal is believed to start at midgestation, when
hypothalamic-pituitary circulation matures, and TSH is se-
creted into the fetal blood (4, 5). As shown in fetal serum
obtained in utero by cordocentesis (6, 7), T4 and free T4 (FT4)
do not clearly increase until 20 –24 weeks gestation, and
free T3 (FT3) is mostly undetectable until after 32 weeks.
Thus, the earlier in pregnancy, the more immature the fetal
gland and the more important the proportion of fetal re-
quirements that are met by the maternal contribution of
hormone. Fetal thyroidal secretion has barely started in
premature neonates of 24 weeks gestational age (GA) and
has been contributing to fetal requirements for only a few
weeks in those born at 27 weeks GA, compared to 3 months
in term (T) babies.
Preterm (PT) babies have low circulating levels of T4 and
FT4 (8); the degree of hypothyroxinemia is greater in the very
premature neonates (9). For years their alterations in circu-
lating parameters of thyroid function have been considered
an expression of their physiological hypophyseal-pituitary-
thyroid immaturity or a manifestation of nonthyroidal ill-
ness, but 2 recent follow-up studies of 640 PT children up to
5 and 9 yr of age (10) and of 400 premature infants up to 2
yr of age (11) have confirmed that severe hypothyroxinemia
plays an important causative role in their frequently im-
paired mental development and disabling cerebral palsy.
Worldwide, the most frequent cause of hypothyroxinemia
is I deficiency, which is at present recognized as the major
cause of preventable mental retardation throughout the
world and a major cause of disabling cerebral palsy. The
severity of the damage is not only related to the degree of the
deficiency, but also to the developmental phase during
which it is suffered, the most severe being the consequence
of I deficiency during the first two trimesters of pregnancy
(12, 13). The I intake of the mother ought to ensure that her
thyroid synthesizes enough hormone for her needs and those
of the developing fetus as well as an adequate supply of I for
fetal and neonatal thyroid function, both in utero and during
lactation. An inadequate I supply might be especially dan-
gerous in the case of PT babies, who have been prematurely
deprived not only of the maternal supply of hormone, but
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also of I, before their own glands have been able to accu-
mulate as much I as in T newborns.
This lead us to investigate the I content of formula prep-
arations used for premature infants and for T neonates (14).
The present study investigates the role of I intake on the
thyroid function of PT infants. It reports the relationship
between I intake and urinary I excretion in PT neonates at
different postmenstrual ages (PMA)1 and compares the re-
sults with those of T neonates. It also investigates whether
their circulating thyroid hormone levels would reach the
same values as those of T neonates once their I intakes be-
come comparable. As will be seen, although a higher I intake
results in an amelioration of several circulating parameters
of thyroid function, a certain degree of hypothyroxinemia
persists for months, even if I intake is comparable to that of
newborn neonates.
Subjects and Methods
Patients
As part of a study on thyroid function of premature babies, we
determined the I intake and I excretion of 115 premature and 28 healthy
T infants born in the Neonatology Unit of the Hospital La Paz (Madrid,
Spain). The premature infants, born between 27–36 weeks GA (body
weights ranging from 900–4200 g), were studied during the first week
of life and every 15 days for up to 2–4 months after birth. The T infants,
born between 37–42 weeks GA, were followed for a shorter period, up
to 1–1.5 months. During the study period I-containing topical antiseptics
were banned from the Neonatology Unit. Infants exposed to external
sources of I as a result of radiological or surgical examinations were
excluded from the study as were those receiving parenteral feeding,
because an I-containing contrast medium had been used to position the
catheters (15). The study was approved by the ethics committee of the
Hospital La Paz.
There were 15 PT infants of 27–30 weeks GA, but only the data
obtained for 10 of them before the onset of parenteral feeding are in-
cluded in the present study as well as all data from the 5 infants who
were always fed orally. Of the 31–36 weeks GA PT babies included in
the study, 52 were healthy; there were 9 small for GA (SGA) infants, and
35 were considered sick PTs with different pathologies, mostly hyaline
membrane disease, transitory distress syndrome, severe infection, car-
diovascular abnormalities, anemia, persistent ductus arteriosus, intra-
cranial hemorrhage, and perinatal hypoxia.
On each occasion, samples of the different formulas or maternal milk
given to each baby were kept for the direct determination of I content,
and the ingested volume over a 24-h period was recorded in each case,
as described previously in more detail (14). The 24-h urine was collected
at each study period for the determination of I and creatinine concen-
trations. Venous blood samples were withdrawn for the determination
of TSH, total T4, FT4, T3, and Tg. When the blood volume obtained was
too small for all of the determinations, only FT4, T3, and Tg were
measured.
I determinations
The concentration of I in formula and milk samples was determined
by a modification of the method described by Benotti and Benotti (16)
for serum, with duplicate 40-mL aliquots of each preparation being
digested in 2 mL chloric acid. The inter- and intraassay coefficients of
variation were 14.7 6 6.7% (6sd) and 12.5 6 1.8%, respectively. The
concentration of I in the urine was determined using 0.5-mL aliquots and
3 mL chloric acid. This method determines the total I content of milk and
urine regardless of its initial chemical form.
Thyroid function tests
Serum TSH (Dynotest TSH from Henning Berlin, Berlin, Germany),
T4 and T3 (RIA kit from Clinical Assays, Baxter, Cambridge, MA), and
FT4 (Two Step Gammacoat Free T4 RIA kit from Clinical Assays) con-
centrations were measured in duplicate by specific RIAs. Tg was mea-
sured by immunoradiometric assay (Dynotest Tg from Henning Berlin).
Statistical analysis
Mean values (6sem) are shown. Data were subjected to one-way
ANOVA after testing for homogeneity of variance. The significance of
the difference between groups was identified by the Newman-Keuls test
for multiple comparisons. All calculations were performed as described
by Snedecor and Cochran (17). Multiple regression and partial corre-
lation analyses were performed using the SPSS program (SPSS Inc.,
Chicago, IL).
Whenever it is stated that a certain variable was higher or lower for
different groups or that correlations existed between the variables, it is
implicit that the differences or correlation coefficients were statistically
significant, at P , 0.05 or less.
Results
I intake
The I intake is calculated from the I concentration of the
formula or maternal milk, which we have previously re-
ported in detail (14), and the volume ingested.
The volume of milk ingested during a 24-h period by all
the PT and T babies at different PMA, corrected for differ-
ences in body weight, is shown in Fig. 1. The very small
premature babies did not ingest the 150–200 mL/kg BWzday
recommended for T babies (18) until they were approxi-
mately 1 month old and weighed 2 kg or more.
Figure 2 shows the I intake of all PT and T infants at
different PMA. As a consequence of the small volume of milk
ingested, the I intake of the 27–30 weeks GA infants and that
of all sick and SGA infants were lower during the first week
of life (7.5 6 1.8 mg I/day) than that of the healthy PT babies
(16.5 6 1.6 mg I/day). The corresponding values at 1 month
of age were, respectively, 13.1 6 2.2 mg I/day (27–30 weeks
GA and sick neonates), 19.3 6 2.5 mg I/day (SGA neonates),
and 25.1 6 2.8 mg I/day (T neonates). The differences dis-
appeared at later ages.
I excretion into urine
Urinary I excretion was calculated from the volume and
the I concentration of the 24-h urine sample. We obtained
data for urinary I concentration in 182 samples, but reliable
24-h urine collection was not always successful. This reduced
1 PMA is the GA plus the postnatal age, in weeks.
FIG. 1. The left panel shows the mean (6SEM) body weights of PT and
T neonates in the present study at different PMA. The right panel
shows the volumes of daily ingested formula or milk in reference to
body weight. The shaded area corresponds to the volume of 150–200
mL/kg BW usually recommended as normal for neonates (18).
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the daily I excretion data to 86 values, from 69 PT and 28 T
infants. The volume of urine was correlated to both the body
weight of the PT baby and the PMA, and the data were fitted
(P , 0.02) by the following equation: volume of urine (mL/
day) 5 162 2 3.6 3 PMA 1 29.7 3 BW, where the PMA is
given in weeks and the body weight in kilograms.
The mean volume of urine was 46.7 6 2.4 mL/kg BWzday
for PT neonates and 33.5 6 4.6 mL/kg BWzday for T infants.
These values are within the normal ranges given by others
for both PT and T infants (18). The volume of urine (in
milliliters per kg BW) decreased with PMA in the PT infants,
whereas no age-related change was observed in T neonates.
The pattern of 24-h urinary I excretion is shown for PT and
T babies in Fig. 2. During the first weeks of life (see the inset
of Fig. 2), I excretion was higher in the majority of the 27–30
weeks GA babies than in the same babies at later postnatal
ages. On the contrary, I excretion in PT infants of 31–36 weeks
GA increased with PMA and, to a lesser degree, with I intake.
When the results were grouped according to PMA and/or
the presence of illness, it was observed that the 27–33 weeks
PMA sick infants excreted approximately 1.5 times the
amount of I into the urine as healthy T babies despite their
lower I intake.
I excretion vs. intake
Figure 2 compares the urinary I excretion with the intake
for both PT and T infants. Initially (Fig. 2, inset), the mean I
excretion was usually higher than the intake, but starting at
about 31–32 weeks PMA, the mean urinary I excretion was
lower than the intake. The differences increased markedly
with age.
When urinary I excretion was plotted against the daily
intake (not shown), it was observed that the majority of PT
babies excreted much less I than they ingested. The 24-h I
intake and urinary excretion were positively correlated, but
with a regression coefficient (n 5 74; r 5 0.35) that, although
statistically significant, was relatively poor for estimation of
I intake from the 24-h urinary excretion data. When the more
numerous data of urinary I concentration (n 5 182) were
considered instead of the 24-h excretion, and PMA and body
weight were also taken into account, the data fitted the fol-
lowing equation (P , 0.001): I intake (mg/day) 5 274.9 1
2.02 3 PMA 1 8.2 3 BW 1 63.7 3 urinary I (mg/mL).
To test how far the I intakes might be assessed from the
above equation when the 24-h collection was incomplete and
only the urinary I concentration was known, we performed
a paired t test comparing the actual measured intakes (21.1 6
1.7 mg I/day) with the calculated ones (21.1 6 1.1 mg I/day);
no difference was found. When this equation was applied to
the T newborns, up to 1.5 months of age there was no dif-
ference between the measured intakes (38.0 6 4.2 mg/day)
and the calculated intake values (37.8 6 2.2 mg/day), sug-
gesting that during this neonatal period the above equation
might also be used to estimate the I intake. This equation
should be considered as merely tentative, as we do not know
whether it would be valid for PT infants receiving a much
higher or lower I intake than those reported in the present
study, in which the maximum I intake was 90 mg/day.
Urinary creatinine
The mean urinary creatinine concentration of PT infants
was lower (7.2 6 0.4 mg/dL) than that of T newborns (13.0 6
3.6 mg/dL; P , 0.001). No reliable correlation was found
between the urinary creatinine concentration and PMA,
body weight, or body length in either PT or T babies. When
the creatinine concentrations were used to calculate the I to
creatinine ratios, the previous correlations between urinary
I concentration and I intake, PMA, and body weight were not
improved, but were actually weakened.
I balance
The daily I balance was calculated as the difference be-
tween the I intake and the I excretion. As evident from the
data shown in Fig. 2, the I balance of very premature infants
appeared to be negative, whereas at about 31–32 weeks of
PMA and later, the I balance was clearly positive. For this
FIG. 2. The mean (6SEM) daily I intake and excretion of PT and T
neonates are shown as a function of PMA. The dashed horizontal line
indicates the recommended daily allowance defined before 1992; the
more recent recommendation (19) of more than 30 mg/kgzday is also
shown as a thin curve. The inset amplifies the urinary I excretion data
between 29–35 weeks PMA. The corresponding I intake is shown as
a thin curve.
FIG. 3. Mean (6SEM) I balance of 27–30 weeks GA neonates at dif-
ferent postnatal ages. The mean I balance was negative (2) in prac-
tically all neonates for the first week after birth, but became positive
(1) in practically all of them by 1 month of age.
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reason, the results of these different groups are described
separately.
Negative I balance
As indicated above, the very immature, 27–30 weeks PMA
PTs showed a different pattern of I balance than the 31–36
weeks PMA healthy PTs; most of the former group were in
negative balance during the first week of life. This negative
balance was greater the more immature the PT baby. As
illustrated in Fig. 3, this condition was only transient, with
the balance changing from negative to positive with increas-
ing PMA.
Many of the 31–36 weeks GA PT infants who were sick and
many of the SGA neonates also excreted more I into the urine
for the first weeks of life than healthy babies of the same
PMA, as summarized in Table 1, despite the fact that their I
intake was not higher.
When the data from all 17 PT babies in negative balance
were considered as a whole, it was found that a negative
balance was more frequent for the first days of postnatal life
(9.0 6 1.6 days) when their mean GA was 32.5 6 0.7 weeks
and their mean weight was less than 2.0 kg (1.9 6 0.2 kg). The
negative I balance of these babies decreased with their PMA
and body weight. The urinary I excretion of the PT neonates
who were in negative balance increased with their I intake.
This finding suggests that the premature infants in negative
balance are unable to retain all the I they are ingesting, and
that an increased intake would not correct their negative I
balance.
When the volumes of urine of all PTs in negative balance
were compared to those of PMA-matched PT babies in pos-
itive I balance, it was observed that the volume of urine
excreted by the former (102 6 8 mL/day) was higher than
that in the PT neonates in positive balance (73 6 9 mL/day).
The negative I balance of these PT babies was not related to
corticosteroid treatment of the mothers at risk of premature
delivery.
Positive I balance
Most of the 31–36 weeks GA healthy PT infants and T
babies were in positive I balance (Table 1), which increased
with I intake and, to a lesser degree, with PMA. As I intake
was also correlated to PMA, multiple regression analysis was
performed to assess the relative contributions of both vari-
ables to I balance. I intake proved to be the major factor
influencing I balance regardless of the stage of maturation,
as measured by PMA.
The urinary I excretion was positively correlated to the I
intake, as indicated for immature infants in negative balance,
but the slope of the linear function was much lower than that
obtained for premature infants in negative balance.
Comparisons between PT and T babies
I balance. Figure 2 not only shows the I intake and urinary I
excretion of PT babies but also those of T infants during their
first 6 weeks after birth. To correct for differences in PMA
between the PT and T neonates, I balance was plotted against
I intake (Fig. 4, left panel). No differences were found between
the linear regressions for PT vs. T infants. This indicates that
when I intake is the same, the amount of I that is retained by
the PT infant is the same as that retained by T infants. The
right panel of Fig. 4 shows the positive I balances of the
premature and full-term neonates as a percentage of their I
intakes and as a function of PMA. As may be seen, the
capacity to retain the ingested I was not constant, but in-
creased with PMA. There was also a great individual vari-
ability around the mean value for a given PMA in the ca-
pacity to retain the ingested I, which was greater the younger
the neonate.
Parameters of thyroid function. As evident from the upper panels
of Fig. 5, the age-related changes in circulating parameters of
thyroid function were different in PT and T infants. The
circulating T3, T4, and FT4 levels in the PT infants increased,
whereas Tg levels decreased, as functions of PMA. On the
contrary, in the T neonates described here we found that
circulating T3 hardly changed with increasing PMA, whereas
FIG. 4. Left panel, Individual values for I balance in both PT and T
neonates are plotted against their I intakes. When, regardless of PMA
and body weight, the I intake was the same, there was no statistically
significant difference between the I balances of PT and T neonates.
Right panel, The positive I balance after 30 weeks PMA is expressed
as a percentage (mean 6 SEM) of the I intake and shown as a function
of PMA for both PT and T neonates.
TABLE 1. Percentage of preterm and term neonates in negative balance
Postnatal
age (days)
Group by GA (weeks)
Term
27–30
31–33 34–36
Sick Healthy Sicka Healthy
5 75 28 11 21 11 7
15 33 14 0 0 0 0
30 0 0 0 0 0 0
Percentages were calculated using as 100% the number of infants in each group with complete 24-h urine excretion data.
a The SGA infants are included in this subgroup.
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T4, FT4, and Tg decreased. Serum TSH (not shown) decreased
during the first week after birth in both PT and T neonates,
but did not later correlate with age.
Figure 6 shows the possible relationship between circu-
lating parameters of thyroid function and I intake. T4 was not
related to I intake in either PT or T infants. TSH (not shown),
FT4, and T3 were correlated with I intake in PT, but not T,
neonates. Circulating Tg decreased with I intake in both
groups. Results were quite similar when these variables were
plotted against the calculated I balance.
It, therefore, appeared of interest to assess whether circu-
lating parameters of thyroid function in premature neonates
would be comparable to those in T infants when their I
intakes (and balance) were the same.
As I intake was also affected by PMA (Fig. 2), it appeared
important to exclude the influence of PMA on the relation-
ships illustrated in Fig. 6. Partial correlation analysis was
performed using only the data from those cases without any
missing variable; all cases where one or more variables were
missing were omitted from the study. This avoided uneven
weights of variables due to differences in the number of data.
We also omitted the data from very sick infants to avoid
hormone alterations that might be a consequence of the neo-
natal pathology. This stringency reduced the study to 90
cases. As summarized in Table 2, this partial correlation
analysis indicated that some of the circulating parameters of
thyroid function were correlated to I intake independently
from PMA; results were different for PT and T neonates
(Table 2). In PT babies, the circulating levels of T3, FT4, Tg,
and TSH were indeed related to I intake, independently of
PMA. On the contrary, the only circulating parameter of
thyroid function that appeared to be related to the I intake
in T babies was the serum concentration of Tg, which de-
creased with increasing intake.
Figure 6 also shows that differences persisted between PT
and T infants in the circulating levels of T4, FT4, and Tg, even
when I intakes were the same. To evaluate the influence of
PT vs. T birth, a multiple regression analysis was performed.
The variables were I intake and circulating T4, FT4, T3, Tg,
and TSH; PT or T birth was the qualitative condition sepa-
rating the data into two groups. When PMA was also entered
among the variables, the conclusions were comparable. The
results are summarized in Table 3 and show that being born
prematurely is the main factor responsible for the lower
circulating levels of T4, FT4, and Tg and persists even when
I intakes are comparable.
This does not mean that parameters of thyroid function are
not ameliorated by increasing the I intake of PT babies, as
their circulating T3, FT4, Tg, and TSH levels are improved
with higher I intakes independently of PMA, as apparent
from Table 2 and in agreement with our previous report (14)
in which I intake of PT neonates above or below 40 mg I/day
was used as the qualitative condition separating the data for
covariance analysis.
Comparisons between premature babies and fetuses in utero. We
have compared the present findings to those obtained in utero
by cordocentesis (7). The result for FT4 is shown in Fig. 7. As
may be seen, the FT4 of premature infants was clearly below
the 95% confidence interval of the values given for fetuses of
the same age in utero. It is unlikely that this is related to
methodological differences between the two different labo-
ratories, as the FT4 levels of the T neonates in the present
study were not lower than those reported by Thorpe-Beeston
et al. (7). Although not shown here, we also found that the
circulating TSH levels of both the PT and T neonates were
FIG. 6. Mean (6SEM) circulating concentrations of T4, FT4, T3, and
Tg are plotted against the daily I intake for both PT and T neonates.
FIG. 5. Mean (6SEM) circulating concentrations of T4, FT4, T3, and
Tg are plotted against PMA for both PT and T neonates.
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below the confidence intervals for the fetal TSH levels, which
are clearly higher than those found in T neonates, their moth-
ers, and nonpregnant adults.
Discussion
I intake
In a previous study (14) we determined the I content of
breast milk, 32 formulas from different brands used in Spain,
and 127 formulas from 14 other countries. Breast milk con-
tained more I (10 6 1 mg I/dL) than the majority of formulas,
especially those for premature infants. The I content ranged
from 1.5–11 mg I/dL for the formulas used in Spain and from
2–17 mg I/dL for those used in the other countries.
Taking into account the amount of formula and/or breast
milk actually ingested by the premature babies, their daily I
intake was far below the recommended daily allowance of
more than 30 mg I/kg accepted since 1992 (19) and hardly
reached the previous recommendations of 40 mg I/day. The
I intake of the T infants was also clearly lower than the more
recently recommended allowance; only a few babies reached
a value of 30 mg I/kg when they were 4–6 weeks old. Present
I intakes are similar to those described for 29 4-week-old PT
babies born in Belgium (20, 21) and for T neonates born in
France (22).
I excretion and I balance
The amounts of I excreted by the full-term babies of the
present study are similar to those reported by Etlin et al. (22).
In the present PT neonates, I excretion changed with PMA,
initially decreasing between 27–30 weeks PMA and then
increasing steadily. PT and full-term infants of similar PMA
excreted the same amounts of I.
Delange et al. (20, 21) reported that 40% of 29 healthy PT
babies studied at 34 weeks PMA were in negative I balance.
A negative balance was also observed in PT babies of the
present study, but was mostly limited to very immature, sick,
or SGA infants. The mean weight of the babies studied by the
above researchers was 1.75 6 0.37 kg, and most of them
appeared to have been born at less than 30 weeks GA. Thus,
our present findings would confirm this report for such
neonates, but not for most of the less immature and healthy
PT neonates. Moreover, the present results show that the
negative I balance is transient and becomes positive as the PT
neonate matures and/or illness is controlled.
Although in most premature neonates both I intake and I
excretion increased with PMA, they did so at different rates;
the proportion of the ingested I that was not excreted into the
urine was not a constant fraction of the intake, with a high
degree of individual variability, especially in the younger PT
neonates, and increased with age. Considering that excretion
of I into the feces represents a minor proportion of excreted
I in both PT and T infants (20, 21), we have assumed that the
positive I balance represents the amount of I that is retained
by the neonate. The present results indicate that this capacity
appears to be the more limited and variable the younger the
TABLE 2. Partial correlation analysis: regression coefficients (r) and significance (P)
T3 T4 Free T4 Tg TSH
Preterm babies
Postmenstrual age vs. r 5 0.28 r 5 0.17 r 5 0.8 r 5 20.96 NS
P , 0.01 P , 0.05 P , 0.01 P ,0.001
Iodine intake vs. r 5 0.3 NSa r 5 0.8 r 5 20.3 r 5 20.3
P , 0.001 P , 0.001 P , 0.001 P , 0.05
Term babies
Postmenstrual age vs. r 5 0.58 r 5 20.9 r 5 20.75 r 5 20.87 NS
P , 0.05 P , 0.01 P , 0.01 P , 0.01
Iodine intake vs. NS NS NS r 5 20.34 NS
P , 0.05
a NS 5 not statistically significant.
TABLE 3. Multiple linear regression analysis: effect of premature
or term birth on circulating T4, FT4, and Tg concentrations
Variable Effect ofprematurity
95% Confidence
interval P
T4 80.1 nmol/L lower 60–100 ,0.001
FT4 20.9 nmol/L lower 18–26 ,0.001
Tga 46.0 ng/dL lower 28–64 ,0.001
a Linearity was obtained after logarithmic transformation.
FIG. 7. The mean (6SEM) concentrations of FT4 corresponding to PT
and T neonates in Fig. 5 as a function of PMA are superimposed on
data published for fetuses in utero by Thorpe-Beeston et al. (7). The
shaded area corresponds to the 95% confidence intervals for the fetal
FT4 data.
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PT neonate, but that it becomes the same as that in T infants
of comparable I intake and PMA.
The facts that PT and T babies were either in negative or
clearly positive I balance and that the proportion of ingested
I that is retained is not constant clearly show that their uri-
nary I excretion cannot be equated to their I intake, as usually
done in field studies of I nutrition in schoolchildren and
adults.
It is very likely that most of the ingested I that is retained
(not excreted into urine or feces) is being taken up by the
neonate’s thyroid gland. It is known that during fetal life the
amount of I accumulating in the gland increases steadily as
a result of a marked increase in both the weight of the gland
and the I uptake (23, 24). Thus, a positive I balance would be
expected during fetal and early postnatal life and would
continue thereafter, as adult glands contain about 10–20 mg
I/gland compared to less than 100 mg at T. We do not know
at which age the thyroidal I content stabilizes, and intake and
excretion become comparable, so that intake may be assessed
from urinary I.
It has been suggested (22) that one of the factors leading
to the negative I balance of PT babies is the immaturity of
their kidneys. Renal immaturity alone, however, does not
offer a convincing explanation; unlike other electrolytes, tu-
bular reabsorption of iodide is negligible, and glomerular
filtration depends entirely on its circulating concentration
(25). Other factors are likely to be involved. Mobilization of
previously accumulated I (or thyroid hormone) pools is
likely to occur, considering that the loss of I into the urine is
greater than its intake. In full term infants neonatal require-
ments for T4 are quite high: the substitution dose for con-
genitally hypothyroid neonates is 8–10 mg T4/kg BWzday
compared to approximately 2 mg/kg BWzday for hypothy-
roid adults. The dose chosen for T4 treatment of premature
babies without congenital hypothyroidism to correct for their
hypothyroxinemia is 8 mg T4/kg BWzday (26). Deiodination
of T4 would represent the release of 12 mg I/day for a PT
neonate weighing 2 kg, an amount clearly higher than the I
intake of the very immature neonates. Therefore, the nega-
tive balance would indicate that the neonates are meeting
their hormonal needs by depleting their prenatal intrathy-
roidal stores. Moreover, the net loss of I into the urine was
greater in PTs receiving the higher I intakes, and this suggests
that the capacity of the thyroid to accumulate iodide and
synthesize T4 is limited, as indicated above.
Parameters of thyroid hormone function
As prematurity is not a normal physiological situation,
circulating levels of T4, FT4, T3, and TSH are usually com-
pared to those of healthy T newborns. Our results are in
general good agreement with those reported in other studies
for both PT and T infants. T4, FT4, and T3 levels are lower in
PT neonates compared to T newborns, increasing progres-
sively with PMA, whereas TSH levels are the same (27–31).
To our knowledge, the possibly independent effects of I
intake vs. PT birth on these parameters of thyroid function
have not been assessed by others. As indicated previously
(14), I intake does affect the circulating levels of FT4, T3, Tg,
and TSH in PT infants independently of their PMA. We also
show here that premature birth by itself affects T4, FT4, and
Tg independently of I intake and PMA. Circulating levels are
lower in PT than in T neonates of comparable PMA and I
intake (or balance), at least up to 44 weeks PMA and an intake
of 80 mg/day. These results also indicate that the thyroid of
PT infants is unable to accumulate I or synthesize and/or
secrete the same amounts of T4 as that of T neonates despite
equal I intake. Indeed, Van den Hove et al. (32) (personal
communication) found that the Tg content and degree of Tg
iodination in the thyroid of PT babies are low compared to
those in T neonates, and the percentage of intrathyroidal I
found as T4 plus T3 is also reduced until they reach a PMA
corresponding to normal T. These findings might also ex-
plain the lower circulating Tg levels of the PT neonates de-
spite the same degree of thyroid stimulation by comparable
levels of circulating TSH.
Proposed interpretation of present results
Birth severs vascular connections between mother, pla-
centa, and fetus, with sudden interruption of transplacental
passage or placental production of nutrients and hormones.
The persistent hypothyroxinemia of the PT neonates could be
at least partly the result of the premature interruption of the
maternal supply of I, thyroid hormone, and placental TRH
occurring at a stage of development when the hypothalamic-
pituitary-thyroid system is not fully mature, and the fetal
thyroid is not ready to meet postnatal requirements.
The hypothesis underlying this proposal is that the pro-
longation of the maternal transfer of thyroid hormone during
the second and third trimesters is a physiological event that
meets part of the fetal thyroid hormone requirements, per-
mitting the fetal thyroid to mature fully, so as to accumulate
I and iodinated Tg, and to produce enough hormone to meet
future needs once the maternal supply is interrupted. Pre-
mature deprivation of the maternal source of I and thyroid
hormone would unduly strain the immature gland of the
neonate, and depletion of previous thyroid stores would be
a likely consequence. Experimental data obtained in rat fe-
tuses deprived of the maternal supply of thyroid hormone
support this possibility; the fetuses manage to meet their
extrathyroidal hormone requirements, but do so at the ex-
pense of the intrathyroidal stores (33).
Tg, T4, and T3 are clearly lower in the thyroids of prema-
ture infants who survived for a few days or weeks after birth
at a mean GA of 35 weeks compared to those of younger
aborted fetuses at a mean GA of 22 weeks (34). Such findings
may be affected by the pathological process that lead to their
death, but the FT4 levels of the present PT infants, many of
whom were healthy, were also clearly lower than those re-
ported for fetuses in utero (7), in conceptual agreement with
the above findings (34), and the hypothesis proposed here.
TSH is necessary for full maturation of the fetal thyroid, as
shown by the atrophy of the gland in cyclocephaly, where the
anterior and posterior lobes of the pituitary are absent (35).
TSH is positively correlated with FT4 in the fetus, indepen-
dently of GA, and continues to increase up to term, even
when adult FT4 levels have been reached (7). TSH levels in
the fetus are much higher than those in T neonates and
adults. As evident when we compared the present results
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with intrauterine TSH levels (7), the high fetal levels drop
abruptly with premature birth, and the maturational effects
of high serum TSH on the thyroid are thus lost. As shown by
the relatively normal pituitary and thyroid development in
anencephaly, where hypothalamus and posterior pituitary
are absent (35), intrauterine TSH secretion is under the con-
trol of extrahypothalamic sources of TRH. High levels of
TRH are found in amniotic fluid, when hypothalamic TRH
is still low and the hypothalamic-pituitary portal system is
not yet fully developed, and in newborns’ cord blood (36, 37).
An important source of TRH that is interrupted at birth is the
placenta (38). The sudden decrease in TRH might also have
effects other than a decrease in TSH secretion, as neuro-
modulator functions have been attributed to extrahypotha-
lamic TRH.
The persistent hypothyroxinemia of the premature neo-
nate might also further delay attainment of full thyroid gland
maturation by several mechanisms that are not mutually
exclusive. In many species thyroid hormones are needed to
attain normal concentrations of TRH in the median eminence
(39), for differentiation of the preoptic nuclei and hypotha-
lamic-hypophyseal tract (40), and for appearance of mono-
aminergic axon terminals and penetration of capillaries into
the median eminence (41). Such effects of thyroid hormone
on the hypothalamic-pituitary portal system might also in-
fluence functions other than TSH secretion, including regu-
lation of GH and glucocorticosteroid economy, which would
also be affected by premature birth.
Consequences of the proposed interpretation of the present
results
The immediate obvious conclusion regarding interruption
of the maternal supply of I is that care should be taken to
provide the recommended minimum I intake, so that the
external I supply would not be a rate-limiting factor for the
synthesis of thyroid hormone once the gland is mature
enough to concentrate iodide and incorporate it into thyroid
hormone. To assess the I intake, the actual volume of food
ingested should be taken into account, not only the I content
of the formula preparation. The addition of supplements
poses no risk, as there is a wide margin between the recom-
mended I intake and a thyroid-blocking I overload.
Even if the I supply is adequate, it may not be sufficient
to avoid the neonatal hypothyroxinemia of premature neo-
nates. Mimicking intrauterine conditions by transient post-
natal treatment with T4 might improve some of the thyroid-
related events, such as maturation of thyroidal T4 and T3
synthesis. Van den Hove et al. (personal communication)
observed that treatment of the very premature (24–32 weeks
GA) PT neonates for 3 days or more with 10 mg T4/kg
BWzday resulted in increases in the degree of iodination of
Tg and the proportion of I found as T4 and T3, to values
similar to those in T neonates.
Several groups have already performed trials to improve
postnatal development of PT neonates with transient post-
natal T4 treatment, obtaining either inconclusive or conflict-
ing results. A recent randomized double blind study involv-
ing 100 PT neonates of less than 30 weeks GA receiving 8 mg
T4/kgzday for 6 weeks and an equal number receiving pla-
cebo has shown that this treatment may improve the devel-
opmental outcome measured at 2 yr of age, although the
latter beneficial effect is restricted to PT infants of less than
27 weeks GA (26).
As discussed above, postnatal substitution with T4 would
compensate for the sudden decrease in FT4 of the premature
neonate compared to the FT4 level to which fetal tissues were
exposed in utero and may well represent an improvement.
However, it would not mimic the intrauterine environment
in other aspects, such as the increased serum TRH and TSH
levels, which might also contribute to maturation of the
hypothalamic-pituitary-thyroid system and other systems
involved in brain development. Obviously, more informa-
tion is needed before such possibilities are considered for
clinical trials.
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